Bersiporocin (DWN 12088) is a first-in-class, orally active small molecule prolyl-tRNA synthetase (PRS) inhibitor with antifibrotic effect.
Prolyl-tRNA synthetase (PRS) is an enzyme that conjugates proline to tRNA, which is an essential process in protein translation.
Bersiporocin (DWN 12088) inhibited collagen and αSMA in human dermal fibroblast.
Bersiporocin (DWN 12088) significantly reduced skin thickness and collagen amount in dose-dependent manner bleomycin (BLM)-induced mouse pulmonary fibrosis model.
Bersiporocin (DWN 12088) increased collagen deposition and significantly impaired lung function in the BLM-induced mouse skin fibrosis model lung.
